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Abstract
Mesenchymal stem cells (MSCs) represent a promising biological therapeutic option as an osteoarthritis 
(OA)-modifying treatment. MSCs secrete factors that can counteract inflammatory and catabolic processes 
and attract endogenous repair cells. The effects of intra-articular injection of MSC secretome on OA-related 
pain, cartilage damage, subchondral bone alterations and synovial inflammation were studied in a mouse 
collagenase-induced OA model. The MSC secretome was generated by stimulating human bone-marrow-
derived MSCs with interferon gamma (IFNγ) and tumour necrosis factor alpha (TNFα). 54 mice were randomly 
assigned to injections with i) MSC secretome from 20,000 MSCs, ii) 20,000 MSCs or iii) medium (control). Pain 
was assessed by hind limb weight distribution. Cartilage damage, subchondral bone volume and synovial 
inflammation were evaluated by histology. MSC-secretome- and MSC-injected mice showed pain reduction 
at day 7 when compared to control mice. Cartilage damage was more abundant in the control group as 
compared to healthy knees, a difference which was not found in knees treated with MSC secretome or MSCs. 
No effects were observed regarding synovial inflammation, subchondral bone volume or the presence of 
different macrophage subtypes. Injection of MSC secretome, similarly to injection of MSCs, resulted in early 
pain reduction and had a protective effect on the development of cartilage damage in a murine OA model. 
By using the regenerative capacities of the MSC-secreted factors, it will be possible to greatly enhance the 
standardisation, affordability and clinical translatability of the approach. This way, this biological therapy 
could evolve towards a true disease-modifying anti-osteoarthritic drug.
Keywords: Mesenchymal stem cell, secretome, osteoarthritis, animal model, pain, synovial inflammation, 
cartilage damage.
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Introduction
Osteoarthritis (OA) is a disabling joint disease 
affecting over 10 % of individuals from the age of 
60 (Zhang and Jordan, 2010). OA is characterised by 
loss of cartilage integrity, subchondral bone changes, 
formation of osteophytes and inflammation of the 
synovial membrane (Berenbaum et al., 2013). The 
interplay between these processes and tissues and 
their exact role in the aetiology and progression of 
the disease is yet unclear. These processes together 
result in pain and functional disability, which are the 
main reasons for patients to seek medical treatment. 
To this date, no curative treatment for OA exists. 
Current treatments mainly aim at the treatment of 
the disease symptoms and not at a durable way of 
modifying pathological osteoarthritic processes. 
Current therapeutic options include life-style 
changes, physical therapy, pain medication and – 
for end-stage OA – joint replacement. Since joint 
arthroplasties have a limited life-span, the need for 
disease-modifying drugs or therapies is high. Ideally, 
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such a therapy would inhibit or repair damage to 
the joint tissues and simultaneously reduce pain and 
disability.
 Mesenchymal stem cells (MSCs) represent a 
promising biological therapeutic option as an OA-
modifying treatment. Stem cells play a pivotal role 
in physiological tissue homeostasis and regeneration 
after tissue injury (Caplan and Dennis, 2006). Next 
to their differentiation potential into several lineages, 
including the chondrogenic lineage, MSCs can 
influence their (micro)environment by secreting 
trophic mediators (Caplan, 2017; Kinnaird et al., 2004; 
Le Blanc and Mougiakakos, 2012; Prockop, 2009; 
Ren et al., 2008; Timmers et al., 2011). These secreted 
factors could possibly counteract inflammatory and 
catabolic processes and attract endogenous repair 
cells (Estrada et al., 2009; Prockop and Oh, 2012; 
Timmers et al., 2011; van Buul et al., 2012). Several 
(pre)clinical studies show promising results for 
intra-articular stem cell injection as a treatment for 
OA (Gupta et al., 2016; Lamo-Espinosa et al., 2016; 
Murphy et al., 2003; Pers et al., 2016; Ter Huurne et 
al., 2012; van Buul et al., 2014). Murphy et al. (2003) 
are the first to show amelioration of degenerative 
changes after intra-articular injection of bone 
marrow-derived MSCs in a caprine OA model. Others 
find diminishment of OA-derived pain (van Buul 
et al., 2014) or synovial inflammation and cartilage 
degradation in pre-clinical studies (Ter Huurne et 
al., 2012). Initial reports from clinical studies indicate 
that intra-articular application of MSCs is safe for OA 
and possibly results in clinical improvement (Gupta 
et al., 2016; Pers et al., 2016).
 The MSC trophic capacities provide the interesting 
option of possibly basing future therapies on the 
secreted factors rather than on the MSCs themselves. 
The importance of the endocrine MSC function 
is further endorsed by the fact that locally- (van 
Buul et al., 2014) or systemically- (Eggenhofer et al., 
2014) applied MSCs show very limited long-term 
engraftment, for which a ʹhit and runʹ mechanism 
is postulated (Prockop, 2009; von Bahr et al., 2012). 
In addition, the MSCs need to be activated to exert 
their trophic effects (Barrachina et al., 2017; Crop et al., 
2010; van Buul et al., 2012). Such an in vivo activation 
is difficult to control or influence and, thereby, likely 
to be subject to large variability. In vitro stimulation 
with, for instance, inflammatory factors provides 
an option to further optimise the use of the MSC 
immunomodulatory abilities.
 The use of the MSC secretome could improve the 
therapeutic efficacy and would greatly enhance the 
clinical applicability of this biological treatment as 
a true disease-modifying anti-osteoarthritic drug. 
The aim of the present study was to explore the anti-
osteoarthritic effects of the human MSC secretome, 
compared to the MSCs, on various outcome measures 
in a collagenase mouse OA model. Injection of human 
MSC secretome was hypothesised to be at least 
as effective as MSCs in reducing OA-related pain, 
cartilage damage, subchondral bone alterations and 
synovial inflammation.
Materials and Methods
Expansion of MSCs
Human bone marrow MSCs were derived from 
heparinised femoral-shaft marrow aspirate of six 
patients undergoing total hip replacement (mean 
age 55.3 ± 10.0 years; female : male ratio 1 : 2) using 
previously described procedures (de Mos et al., 2007), 
after written informed consent and approval by the 
medical ethical committee (protocol METC-2004-142). 
Briefly, bone marrow cells were plated at 50,000 cells/
cm2 and, after 24 h, the flasks were washed to remove 
non-adherent cells. Then, MSCs were trypsinised 
[0.25 % trypsin/ethylenediaminetetraacetic acid 
(EDTA) solution (Life Technologies)] and seeded 
in cell culturing flasks at a density of 2,300 cells/
cm2 in expansion medium consisting of minimal 
essential medium alpha (αMEM; Gibco), 10 % heat-
inactivated foetal calf serum (FCS; Gibco), 1.5 µg/
mL fungizone (Invitrogen), 50 µg/mL gentamicin 
(Invitrogen), 25 µg/mL ascorbic acid-2-phosphate 
(Sigma-Aldrich) and 1 ng/mL fibroblast growth 
factor 2 (FGF2; AbD Serotec, Oxford, UK). Cells 
were cultured in an incubator at 37 °C, 5 % CO2 
and 90 % humidity. Medium was refreshed twice a 
week. MSCs were passaged at approximately 70 % 
confluency. MSCs used for in vivo experiments were 
characterised by fluorescence-activated cell sorting 
(FACS) analysis and resulted positive for CD73, 
CD90, CD105 and CD166 and negative for CD11C, 
CD31 and CD45 (data not shown). de Mos et al. 
(2007) show tri-lineage differentiation of cells isolated 
following this procedure. The viability of the MSCs 
was evaluated after trypsinisation and before being 
injected or seeded for obtaining the secretome: less 
than 5 % of the cells were dead, as indicated by trypan 
blue positive staining. Human MSCs from end-
stage OA donors were used to increase the clinical 
translatability of the study.
Preparation of MSC secretome
To produce the MSC secretome, passage 3 MSCs were 
plated at a density of 3.5 × 104 cells/cm2 and cultured 
for 24 h in expansion medium. After 24 h, cells were 
activated to secrete immunomodulatory factors by 
culturing for 24 h in stimulating medium (van Buul 
et al., 2012). This stimulating medium consisted of 
αMEM supplemented with 1.5 µg/mL fungizone, 
50 µg/mL gentamicin, 1 % insulin-transferrin-
selenium (ITS; Biosciences), 50 ng/mL interferon 
gamma (IFNγ; PeproTech) and 50 ng/mL tumour 
necrosis factor alpha (TNFα; PeproTech). After 
24 h of stimulation, MSCs were washed five times 
with phosphate-buffered saline (PBS; Gibco). To 
collect the paracrine factors, collecting medium was 
added, consisting of only αMEM with 0.05 % bovine 
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serum albumin (BSA; Sigma-Aldrich) – to stabilise 
the secreted factors and as an adhesive for smaller 
molecules to bind to and to be retained after the 
concentration step – and without phenol red – which 
can mimic an oestrogen and, therefore, influence 
cell behaviour in vivo. 1 mL of collecting medium 
was added per 2.0 × 105 MSCs. MSC secretome was 
collected after 24 h and centrifuged at 700 ×g for 
8 min to remove cell debris. The secretome equivalent 
of 20,000 MSCs, a number of cells previously used 
in a mouse collagenase OA model (Ter Huurne et 
al., 2012), was planned to be injected in a murine 
knee joint. To achieve this in an end volume of 
6 µL, suitable for injection in a mouse knee joint, 
the MSC secretome was concentrated by loading on 
a 3 kDa cut-off filter (Amicon Ultra-4 Centrifugal 
Filter Unit, UFC800324, Merck Millipore B.V.) and 
spinning down for 20 min at 4000 ×g. Molecules 
above 3 kDa were retained. The concentrated MSC 
secretome was collected, aliquoted and stored at 
− 80 °C for further use. Concentrated secretome was 
checked for indoleamine 2,3-dioxygenase (IDO) 
activity by measuring the metabolite L-kynurenine 
concentration, as described before (van Buul et al., 
2012). Briefly, the concentrated secretome was diluted 
10 times and 200 µL of the diluted sample were 
mixed with 30 % trichloroacetic acid (Sigma-Aldrich), 
incubated at 50 °C for 30 min and spun down at 
10,000 ×g for 5 min. 75 µL of supernatant were added 
together with 75 µL of 7,12-dimethylbenzanthracene 
(DMBA; Sigma-Aldrich) (20 mg/mL in acetic acid). 
The extinction was measured at 490 nm in a Versamax 
microplate reader (Molecular Devices, LLC, San 
Jose, CA, USA). A L-kynurenine concentration of 
33.7 ± 4.5 µM was calculated considering the dilution 
factor, indicating substantial immunomodulatory 
MSC activity. To develop the concentrated secretome 
production protocol, the secretomes of three 
MSC donors were used. Increased IDO activity 
confirmed the anti-inflammatory capacity of the 
donors. A minimum of 0.05 % of BSA was needed 
in the secretome to maintain the secreted cytokines 
and growth factors, based on the concentrations 
of interleukin 6 (IL-6). The concentration of IL-6 
in the concentrated secretome was measured by 
enzyme-linked immunosorbent assay (ELISA; R&D-
systems) according to the protocol supplied by the 
manufacturer. In the obtained batch of secretome, 
the concentration of IL-6 was 238 ± 42 ng/mL if 
0.05 % BSA was present and lower and below the 
detection limit if no BSA was present (data not 
shown). Later, this developed protocol was used 
to produce concentrated secretomes of three new 
donors, in which the IDO activity was tested to 
confirm the donors’ anti-inflammatory capacity. The 
MSC secretomes of these donors were pooled and 
used for in vivo experiments. Control medium was 
subjected to the same handling as the MSC secretome, 
including 24 h incubation and concentration, except 
for the exposure to the MSCs, and stored at − 80 °C 
for further use.
Animal experimental design
Experiments were performed on 54 male C57/Bl6 
mice, age 12 weeks (Harlan Netherlands B.V., Horst, 
the Netherlands), with approval of the animal ethical 
committee (#EMC 116-14-03). Mice were housed in 
groups of three or four mice per cage, under 12 h 
light-dark cycle at a temperature of 24 °C and had 
access to water and food ad libitum at the animal 
testing facilities of the Erasmus MC, University 
Medical Centre, Rotterdam, the Netherlands. Before 
the start of the experiments, mice were allowed to 
acclimatise for a week. OA was induced unilaterally 
in the knee of all mice by 2 intra-articular injections 
of 3 units collagenase type VII (Sigma-Aldrich) at 
days − 7 and − 5. All intra-articular injections were 
applied with an injection volume of 6 µL and under 
2.5 % isoflurane anaesthesia, using a 50 µL glass 
syringe (Hamilton Company, Ghiroda, Romania) 
and a 30 G needle (BD). Contralateral control knees 
were kept naïve and were not injected. Mice were 
randomly assigned to either treatment group A, 
which was injected with 20,000 passage 3 MSCs 
in 6 µL concentrated medium, treatment group B, 
injected with MSC-secretome from 20,000 MSCs 
concentrated in 6 µL medium or control group C, 
injected with 6 µL control medium (n = 11 mice per 
group, 1 mouse in the control group was not assessed 
by histology due to technical problems). MSCs 
used in group A were not activated by stimulating 
medium prior to injection, since in vivo activation by 
the osteoarthritic environment was considered to be 
more clinically relevant. All groups received three 
consecutive injections: the first injection (referred 
to as day 0) was given 7 d after the first collagenase 
injection and repeated at day 2 and 4. Once weekly, 
weight distribution over the left and right hind limbs 
was evaluated as an indicator of pain (for the method 
see below). Animals were euthanised at day 21 after 
start of treatment and knee joints were harvested for 
histological analysis. To assess the early effects of the 
treatments – especially on synovial inflammation – 
an additional experiment was performed consisting 
of 7 mice in each group (same 3 treatment groups 
as mentioned previously, n = 7 mice per group). 
These animals underwent identical OA induction 
and treatment protocols. They were euthanised at 
day 5 after the treatment start and knee joints were 
prepared for histological evaluation.
Measurement of hind limb weight distribution
Hind limb weight distribution, as an indicator of 
pain, was monitored by an Incapacitance Tester 
(Linton Instrumentation, Norfolk, UK), as previously 
described (Khatab et al., 2018; van Buul et al., 2014). 
Mice were positioned on the Incapacitance Tester 
with each hind limb resting on a separate force 
plate. Animals were habituated to the apparatus, 
starting 2 weeks prior to the experiments. The 
examiner performing the measurements was 
blinded to the data registration. Measurements 
were automatically stored in a computer database. 
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A baseline measurement was performed at day 
– 7, just before the induction of the OA. Follow up 
measurements were performed 1 week after OA 
induction at day 0, just before therapy administration 
and at day 7, 14 and 21. After the 3 weeks of data 
collection, upon data analyses, measurements with 
a registration below 3 g (< 10 % of total body weight) 
per hind limb or less than 10 g (< 30 % of total body 
weight) in total over both hind limbs were excluded. 
30-45 measurements were recorded per time point, 
15 measurements per time point per animal were 
available on average. For each time point per mouse, 
the average of these measurements was used to 
calculate the percentage of weight on the affected 
limb as an indication of pain in the affected limb. The 
average value per measurement time point was used 
for statistical analyses.
Histology
Knees were fixed in 4 % formalin (v/v) for 1 week, 
decalcified in 10 % EDTA for 2 weeks and embedded 
in paraffin. Coronal sections of 6 µm were cut for 
analysis of synovial inflammation and cartilage 
damage.
Cartilage damage
Cartilage damage was evaluated on thionine-stained 
sections by two observers blinded to the treatment 
groups using the scoring system described by 
Glasson et al. (2010). Briefly, this score ranges from 
0, for normal cartilage, to 6, for cartilage with clefts 
and erosion to the calcified cartilage in > 75 % of the 
articular surface. For each knee, cartilage quality in 
the lateral and medial compartment – both femur 
and tibia – of the knee was scored on 3 sections at 
standardised locations in the knee with 180 µm 
between the sections, leading to a maximum score 
of 12 per compartment and a total summed score 
of 36 per compartment. For each compartment, the 
maximum and summed score assigned by the two 
blinded observers was averaged. Since OA damage 
was most pronounced in the lateral compartment 
(data not shown), these data were considered for 
further analyses.
Subchondral bone changes
The percentage of subchondral bone per total volume 
of subchondral space between calcified cartilage and 
growth plate was calculated. Measurements were 
performed using ImageJ software (NIH). For each 
knee, a region of interest was drawn in a standardised 
way on 3 sections at standardised locations in 
the knee, with 180 µm between the sections. The 
region of interest was drawn between the calcified 
cartilage on the top and the growth plate on the 
bottom. The insertion of the cruciate ligaments was 
used as medial boundary and the lateral side of the 
growth plate as lateral boundary, taking care not 
to include osteophytes. Since the largest amount of 
remodelling was found in the medial compartment 
(data not shown), these data were considered for 
further analyses.
Synovial inflammation
Sections were stained with haematoxylin and eosin 
for synovial inflammation assessment. Images were 
acquired using the NanoZoomer Digital Pathology 
program (Hamamatsu Photonics, Ammersee, 
Germany). Synovial thickness was measured from 
the capsule to the superficial layer of the synovial 
membrane at the medial and lateral sides of the 
parapatellar recesses (three positions per section), 
as previously described (Khatab et al., 2018). These 
measurements were performed on three sections 
per knee, with 180 µm between the sections. The 
thickness measurements were averaged to obtain a 
single value per knee joint.
 To evaluate macrophage subtypes in the synovial 
membrane, inducible nitric oxide (iNOS) was used as 
a marker of pro-inflammatory macrophages, CD163 
as a marker of anti-inflammatory macrophages and 
CD206 as a marker of tissue repair macrophages 
(Park et al., 2017; Utomo et al., 2016). For this 
purpose, sections were deparaffinised, washed and 
heat-mediated antigen retrieval was performed for 
CD163 and CD206, by placing the slides in 95 °C 
citrate buffer (pH 6) for 20 min. Antigen retrieval 
for iNOS was performed by placing the slides in 
95 °C Tris-EDTA buffer (pH 9) for 20 min. Blocking 
of specific binding was performed with 10 % goat 
serum (Southern Biotech, Birmingham, AL, USA) for 
30 min. Hereafter, sections were incubated for 1 h 
with the primary antibodies iNOS (2.0 µg/mL, #15323, 
Abcam), CD163 (0.34 µg/mL, #182422, Abcam) and 
CD206 (2.5 µg/mL, #64693, Abcam), followed by 
30 min incubation with a biotinylated anti-rabbit 
Ig link (HK-326-UR, Biogenex, Fremont, CA, USA), 
diluted 1 : 50 in PBS/1 % BSA. Thereafter, sections 
were incubated with an alkaline-phosphatase-
conjugated streptavidin label (HK-321-UK, Biogenex) 
diluted 1 : 50 in PBS/1 % BSA. To reduce background, 
endogenous alkaline phosphatase activity was 
inhibited with levamisole (Sigma-Aldrich Chemie). 
New Fuchsin (Fisher Scientific) and Napthol AS-MX 
phosphate (Sigma-Aldrich Chemie) substrates were 
used for colour development and counterstaining was 
performed with haematoxylin. As a negative control, 
rabbit IgG antibody (DakoCytomation, Glostrup, 
Denmark) was used. The sections were ranked from 
the weakest to strongest staining for iNOS, CD163 
and CD206 by two observers blinded to the treatment 
groups. When multiple sections had similar staining 
strength, i.e. amount of positive cells, the rank mean 
was assigned to each section. The average of the ranks 
assigned by the two observers to the knee for a certain 
staining was used for further analyses.
Statistical analysis
Data were analysed with IBM SPSS statistics 24 
(SPSS, Chicago, IL, USA). For the effect on weight 
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distribution, normality per measurement time 
point was confirmed with a Shapiro Wilk test. For 
pain measurements, the collagenase effect was 
analysed using a two-tailed paired t-test before 
and after OA induction. For treatment effects, all 
groups were compared using a linear mixed model 
in which measurement time point and treatment 
were considered fixed factors and weight-bearing a 
dependent factor. Post-hoc analyses were performed 
by Bonferroni correction. Quantitative histology data 
were analysed by means of a univariate general linear 
model where measurement time point and treatment 
were considered fixed factors and subchondral bone 
volume percentage a dependent variable. Semi-
quantitative histology scores were compared using 
a non-parametric Mann-Whitney test, to assess 
collagenase or measurement time point effects, and 
Kruskal Wallis test, to assess treatment effects within 
different time points. Binominal histology data were 
analysed by means of χ2 test for multiple group testing 
and Fisher’s exact test for comparing separate groups. 
For all tests, p < 0.05 was considered statistically 
significant. Correlation analysis was performed by 
means of a Spearman’s ρ test. For the interpretation 
of the correlation coefficient, the absolute value of 
rs was used, classifying the correlations as weak 
(< 0.39), moderate (0.40-0.59), strong (0.60-0.79) and 
very strong (> 0.80). Correlations were regarded 
significant if p < 0.05.
Results
Injection with MSC secretome resulted in early 
pain reduction
Weight distribution over the hind limbs was 
determined as an indicator of pain (Fig. 1). On day 
− 7, just before induction of OA, the average weight 
on the right hind limb for all groups was 49.9 ± 1.7 %, 
indicating no difference between left and right 
hind limbs. 7 d after induction of OA (day 0, before 
treatment), 41.2 ± 6.3 % of the weight was distributed 
on the OA-affected limb, indicating pain when 
compared to before OA induction (Fig. 1, p < 0.001). 
No differences between treatment groups were found 
before both OA induction and treatment. At day 7, 
significantly more weight was put on the OA-affected 
limb by MSC-secretome- (49.5 ± 2.2 %) and MSC- 
(47.7 ± 2.9 %) injected animals at day 7, compared to 
control animals (43.6 ± 4.2 %; p = 0.001 and p = 0.023 
respectively). Furthermore, the MSC-secretome- and 
MSC-injected animals put significantly more weight 
on their OA-affected limb on day 7 as compared to 
day 0 (p = 0.013 and p = 0.032 respectively, not shown 
in graph) whereas control animals did not, indicating 
early normalisation in weight bearing and pain 
reduction in treated animals. At day 14 and day 21, 
all groups showed less pain when compared to day 
0, whereas no significant difference between groups 
was observed.
MSC secretome had a protective effect on cartilage 
damage but not on subchondral bone remodelling
To evaluate cartilage damage, all knees were scored 
21 d after treatment (Fig. 2a,b, score range 0-12 for 
max score and 0-36 for sum score). Due to a high 
variability in the development of OA, no significant 
differences were found by non-parametric tests when 
comparing OA scores between knees treated with 
collagenase and healthy knees or among any of the 
treatment groups (Fig. 2a,b). Since some animals 
showed a clear OA development whereas others did 
not, binominal data were generated, where a max 
OA score of > 2 was considered as having OA and a 
score of ≤ 2 as not having OA (Table 1). A significant 
difference when comparing all groups was found 
using χ2 test (p = 0.044), after which separate groups 
were tested using Fisher’s exact test. In the control 
group, where collagenase was injected but no MSC 
treatment was applied, more knees had OA than 
in the healthy group (p = 0.012). OA development 
was prevented in knees that were treated with MSC 
secretome or MSCs, in which no significant difference 
was found between healthy knees (p = 0.238 for both). 
No significant effect was observed when directly 
comparing MSC-secretome- or MSC-injected knees 
to control knees (p = 0.183 for both).
 Identical analyses were performed for the sum 
OA scores (Fig. 2b), where a sum OA score of > 3 
was considered as having OA and a sum score of ≤ 3 
as not having OA (data not shown). Although the 
control group contained most animals with OA, no 
significant difference among all groups regarding 
sum OA scores was found by χ2 test; consequently, 
no further analyses were performed to evaluate 
treatment effects.
Fig. 1. Assessment of pain with hind limb weight 
distribution. Hind limb weight distribution was 
measured as an index of joint pain. OA induction by 
collagenase caused significant pain. MSC secretome 
and MSC injection resulted in normalisation of 
weight bearing at day 7, at which time point pain 
was significantly reduced when compared to the 
control group and to day 0. At day 14 and 21, all 
groups showed significantly less pain as compared 
to day 0. Data shown as mean ± SD, n = 11/group, 
a p < 0.05; b p < 0.001. 
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 To further appraise the influence of MSC secretome 
on OA processes, the effects on subchondral bone 
remodelling at day 5 and day 21 after treatment were 
determined (Fig. 3a,b). Although subchondral bone 
volume appeared to be slightly decreased in knees 
with induced OA, no significant difference between 
any of the groups was found.
MSC secretome had no effect on synovial membrane 
inflammation
All collagenase-injected knees displayed a 
significantly thickened synovial membrane when 
compared to healthy knees at 5 and 21 d after 
treatment (Fig. 4a,b; p < 0.001 for both time points). 
No significant difference was observed between 
treatment groups within each time point. Overall, 
synovial membrane thickness was largely reduced 
over time between day 5 and day 21 for all groups 
(p < 0.001).
 To further analyse the synovial inflammation 
processes, the presence of different macrophage 
subtypes was assessed by the presence of iNOS+ 
(pro-inflammatory), CD163+ (anti-inflammatory) 
and CD206+ (tissue repair) cells in the different 
treatment groups. The presence of iNOS+ cells was 
not significantly different between the treatment 
groups at each time points individually or between 
both time points (Fig. 4c). A trend was observed 
towards a lower presence of iNOS+ cells in the control 
vs. MSC group at day 5 (p = 0.053). A significant 
increase in the presence of CD163+ and CD206+ cells 
was found in all groups at day 21 vs. day 5 (p < 0.001 
and p = 0.004, respectively), but no differences in the 
presence of CD163+ or CD206+ cells were observed 
between treatment groups at both time points.
 To further unravel the inflammatory processes and 
their relation to pain and structural damage, these 
aspects were correlated to the presence of the different 
macrophage subtypes (Table 2). An increased staining 
for CD163+ cells (anti-inflammatory macrophages) 
was moderately associated with a thinner synovial 
membrane [correlation coefficient (CC) = − 0.397, 
p = 0.003, all treatment groups combined], but not 
with cartilage damage. This could indicate that more 
staining for anti-inflammatory macrophages was 
related to less synovial inflammation. In addition, 
the amount of CD163+ staining was moderately 
associated with less pain at day 14 (CC = − 0.394; 
p = 0.026), possibly pointing towards pain reduction 
in the presence of anti-inflammatory macrophages. 
CD163+ staining was weakly associated with the 
intensity of CD206+ staining (CC = 0.281; p = 0.042), 
representing the co-presence of anti-inflammatory 
and repair-related macrophages. CD206+ staining was 
moderately associated with both lateral (CC = 0.465; 
p = 0.007) and medial OA damage (CC = 0.412; 
p = 0.028), but not with synovial thickness. This could 
indicate a higher presence of tissue-repair-associated 
macrophages in the situation of more cartilage 
damage. Lastly, a moderate association between 
subchondral bone volume and synovial thickness was 
found (CC = 0.496, p < 0.001), possibly indicating an 
increased bone remodelling with increased synovial 
inflammation. No significant associations were found 
between iNOS+ staining and pain, synovial thickness 
or cartilage damage. There were no associations 
between pain and synovial thickness, OA score or 
subchondral bone volume.
Discussion
Injection of human MSCs secretome resulted in an 
early pain reduction and had a protective effect on 
the development of cartilage damage in a mouse 
collagenase-induced OA (CIOA) model. No clear 
treatment effects were observed on subchondral 
Fig. 2. Maximum and sum OA scores for the lateral compartment were not significantly different 
between any of the groups (a,b). Individual values are shown, solid lines represent median values, dotted 
line represents cut-off value for definition of OA development or not. 
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Table 1. OA incidence in healthy and treated knees. A maximum OA score of 2 was used as cut-off. A 
significant difference was found when comparing the binominal data of OA incidence in control versus 
healthy knees. No significant difference was found between MSC-secretome or MSC-treated knees as 
compared to healthy knees, indicating a chondroprotective effect. ap < 0.05.
OA incidence Healthy Control MSC secretome MSC
AO 0 5 2 2
Non-OA 11 5 9 9
Percentage AO 0.0 % 50.0 % 18.2 % 18.2 %
bone remodelling or synovial inflammation, although 
several significant moderate correlations between 
macrophage phenotypes and OA characteristics 
were found. These correlations enhanced the 
understanding of the inflammation role in the mouse 
CIOA model. MSC secretome injections were at 
least as effective as MSCs in the amelioration of OA-
related pain or morphological changes, endorsing the 
potential of this cell-free approach.
 MSCs diminish several OA characteristics, 
as demonstrated in pre-clinical and some initial 
clinical studies (Gupta et al., 2016; Lamo-Espinosa 
et al., 2016; Murphy et al., 2003; Pers et al., 2016; Ter 
Huurne et al., 2012; van Buul et al., 2014). Although 
intra-articular injection of MSCs does benefit the 
joint after OA induction, the MSCs themselves are 
not detectable 3 weeks after injection (van Buul et 
al., 2014). This limited presence of the MSCs in the 
joint is also observed by Diekman et al. (2013) and 
Mak et al. (2016), the latter suggesting that this is 
due to differentiation, migration or cell death. Thus, 
although long-term engraftment is not present, intra-
articular injection of MSCs can have a beneficial effect, 
leading Prockop (2009) and von Bahr et al. (2012) to 
postulate the ‘hit-and-run’ mechanism, in which 
the MSC-secreted factors play an important role. 
The use of the therapeutic MSC secretome without 
actual employment of cells originates from the 
cardiovascular field (Gnecchi et al., 2005). Although 
the longevity of the secreted factors is expected to be 
even lower than that of the MSCs, they seem to have 
an effect in vivo, possibly by activating a cascade of 
reactions.
 It is not known which factor(s) in the MSC-
secretome is responsible for the anti-osteoarthritic 
effect. Next to IL-6, prostaglandin E2 (PGE2), TNF-
stimulated gene 6 (TSG-6) and hepatocyte growth 
factor (HGF), which are partly responsible for some 
effects in various disease models (reviewed by 
Madrigal et al., 2014), extracellular vesicles secreted 
by the MSCs are speculated to be important for injury 
reduction and repair in, for example, experimental 
myocardial infarction, stroke or endotoxin-induced 
lung injury, as reviewed by Konala et al. (2016) and 
Rani et al. (2015). In the orthopaedic field, Platas et 
al. (2013) demonstrate protective effects of adipose-
tissue-derived MSC secretome in an inflammatory 
in vitro chondrocyte model. Other groups show 
beneficial effects of MSC-derived exosomes and/or 
particles in various pre-clinical OA models in vivo 
(Cosenza et al., 2017; Tao et al., 2017; Wang et al., 2017; 
Zhang et al., 2018; Zhu et al., 2017), as reviewed by 
Toh et al. (2016). Although the extracellular vesicle 
content in the MSC secretome was not quantified, a 
large proportion of the extracellular vesicles, mainly 
the exosomes (10-100 nm) and microvesicles (100-
1000 nm), was most likely retained (Morhayim et 
al., 2014). The retention of the extracellular vesicles 
is described by the manufacturer when using the 
Amicon Ultra-4 Centrifugal Filter Unit, even with a 
larger 10 kDa cut-off. Therefore, the observed effects 
were due, possibly, to the MSC extracellular vesciles, 
which provide a controlled microenvironment and 
protect their content from degradation in vivo thanks 
to their bilayered membrane (Zheng et al., 2018). 
These in vivo effects were promising and encourage 
the further unravelling of the MSC therapeutic 
function. Nevertheless, these cited studies are based 
on extracellular vesicles isolated from the secretome 
of young animals, human embryonic stem cells or 
genetically modified cells. To our knowledge, this 
was the first evidence of in vivo anti-osteoarthritic 
effects of MSC secretome isolated from aged human 
donors with end-stage OA.
 Although promising, the MSC secretome could 
also contain components causing an adverse effect. 
Additional proteomic studies are needed to examine 
the exact components of the secretome, to further 
elucidate its working mechanism. The secretome 
use would greatly reduce problems linked to safety 
and legal issues related to cell-based therapies, 
thereby emphasising the clinical relevance of these 
findings. If the MSC secretome could be used in OA 
therapies as an alternative to MSCs, the possibilities 
to provide a more standardised and affordable 
therapeutic option would be largely increased. 
Good manufacturing practice (GMP) facilities could 
become more centralised and large quantities of MSC 
secretome could be generated from well-defined, 
selected batches of MSCs. The secretome could 
be checked for predetermined concentrations of 
cytokines and growth factors. These could either be 
preferable or non-preferable cytokines depending 
on the application. Simultaneously, problems raised 
by legal and safety issues regarding the use of cell 
therapy would be decreased. Nevertheless, such an 
approach might bring new safety and regulatory 
issues, such as finding suitable MSCs donors for 
maintaining a large scale secretome production in 
vitro.
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Fig. 3. No treatment effect on subchondral bone volume. (a,b) The subchondral bone volume was calculated 
as a percentage of total volume of subchondral space between calcified cartilage and growth plate, depicted 
in a. No differences were found between healthy and OA-induced knees or any of the treatment groups. 
Data shown as mean ± SD for medial tibial plateau, n = 7/group at day 5 and  n = 11 at day 21; healthy 
knees n = 5 at day 5 and n = 6 at day 21.
Fig. 4. No treatment effect on synovial membrane thickness (a,b) Synovial membrane thickness decreased 
in time. Individual values are shown, lines represent mean values. (c) A trend towards more iNOS+ staining 
was observed in the MSC group at day 5. The amount of (d) CD163+ and (e) CD206+ staining increased with 
time. Box and whiskers plots are shown, lines represent median values. ). ap < 0.001; bp = 0.053; cp < 0.005
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 The pain reduction by treatment with MSC 
secretome or MSCs, as seen in the present study, 
lasted for the entire experiment. Interestingly, the 
control group showed a pain reduction as well, 
only at a later time point. This indicated a general 
pain reduction as the natural course of the used 
OA model, as found before (Khatab et al., 2018). 
This is also described by Adaes et al. (2014), who 
find a maximum of pain sensation 1 week after OA 
induction by collagenase in a rat model. This pain 
sensation gradually decreased in a period of 4 to 
6 weeks after induction. Clinically, OA-related pain 
is correlated to the radiological presence of synovial 
inflammation as well as bone marrow lesions, as seen 
by magnetic resonance imaging (Carotti et al., 2017). 
In the CIOA model, both synovial inflammation 
and dynamic subchondral bone changes are present 
(Botter et al., 2011; van der Kraan et al., 1990). 
Osteochondral angiogenesis is shown in OA, in which 
neural growth factor expression and sensory nerve 
growth may be the links to perceived pain (Mapp 
and Walsh, 2012). Since cartilage itself is an aneural 
tissue, this is a plausible mechanistic explanation for 
pain perception in OA. Subchondral bone changes 
are biphasic during OA: an initial atrophic phase 
leads to a decreased subchondral bone volume, after 
which a hypertrophic phase initiates the increase in 
bone volume (reviewed by Yuan et al., 2014). Botter 
et al. (2011) find initial thinning of the subchondral 
bone plate 2 weeks after OA induction in a mouse 
CIOA model, after which, at 10 weeks, subchondral 
bone thickness returns to levels comparable to 
before OA induction. Clinically, fully eroded joint 
regions display a thickened subchondral bone region, 
whereas partially eroded areas show a thinner 
subchondral bone plate as compared to non-eroded 
regions (Hwang et al., 2008). Regarding the effect of 
mesenchymal cells on subchondral bone, Parrilli et al. 
(2017) show that injection of adipose-derived stromal 
cells counteracted accelerated bone turnover in a 
rabbit OA model. A trend towards a decrease in bone 
volume was observed in the used CIOA model, but 
no effects of the different treatments nor a correlation 
between pain reduction and subchondral bone 
volume were found. The discrepancy in the absence 
of an MSC effect in the present study could possibly 
be due to the fact that subchondral bone volume was 
calculated on histological slides instead of on true 3D 
volumetric or densitometric bone measurements by 
micro-computed tomography (µCT).
 The first phase after collagenase injection 
in the CIOA model is an inflammatory phase, 
leading to synovial thickening and infiltration with 
inflammatory cells within 1 week. Cartilage damage 
and other pathological OA-related changes become 
more pronounced after 2 to 4 weeks, with marked OA 
changes found after 6 weeks (Adaes et al., 2014; van 
der Kraan et al., 1990). Although a clear pain reduction 
in MSC-secretome- and MSC-treated animals was 
observed 1 week after treatment – which is 2 weeks 
after OA induction – no treatment effects on synovial 
thickness or synovial macrophage phenotype were 
Parameters tested by Spearman ρ
Correlation 
coefficient Strength p-value Interpretation
CD163 + cells
Synovial membrane 
thickness − 0.397 Moderate 0.003
Higher CD163 staining intensity 
associated with thinner synovial 
membrane
CD163 + cells Pain day 14 − 0.394 Moderate 0.026
Higher CD163 staining intensity 
associated with less pain at day 
14a 
CD163 + cells CD206+ cells 0.281 Weak 0.042
Higher CD163 staining intensity 
associated with more repair 
macrophages
CD206 + cells Lateral OA score 0.465 Moderate 0.007
Higher CD206 staining intensity 
associated with more lateral OA 
damage
CD206 + cells Medial OA score 0.412 Moderate 0.019
Higher CD206 staining intensity 
associated with more medial OA 
damage
Subchondral 
bone volume
Synovial membrane 
thickness 0.496 Moderate < 0.001
Larger subchondal bone volume 
associated with thicker synovial 
membrane
Table 2. Selection of correlations coefficients between the parameters tested. Associations between CD163+ 
and CD206+ staining and various OA aspects as reported in previous figures. a Weight distribution on the 
affected limb was measured as an indicator of pain; the higher the percentage of weight on the affected limb the 
less pain, thus giving a negative association with CD163+ cells. Synovial thickness, subchondral bone volume 
and macrophage data based on day 5 and day 21 time points, OA score based on day 21 time point only.
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Discussion with Reviewers
Lucienne Vonk: What would the outcome be using 
the secretome of not pre-activated MSCs?
Authors: Several studies show that the secretome 
of activated MSCs has better anti-inflammatory 
capacities than non-activated cells (Barrachina et al., 
2017; Crop et al., 2010; van Buul et al., 2012). In the 
present in vitro study using human OA cartilage and 
synovium explants, no anti-inflammatory effects of 
the secretome from not pre-activated MSCs were 
observed. Based on these results, it is unlikely that 
secretome of not pre-treated MSCs would give an 
effect in the CIOA murine model.
Lucienne Vonk: Would extracellular vesicles 
perform as well as the whole secretome?
Authors: Based on the used production protocol, 
the MSC secretome was expected to contain both 
soluble factors secreted in the collecting medium as 
well as extracellular vesicles. Since the content of the 
extracellular vesicles can be different from the soluble 
factors present in the secretome, it is possible that 
the effect of isolated extracellular vesicles would not 
entirely match that of the entire secretome. Future 
studies on this topic would be necessary to elucidate 
this aspect.
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Lucienne Vonk: Would pre-activated MSCs perform 
even better?
Authors: MSCs can respond to their environment and, 
that way, produce the cytokines and growth factors 
needed at that moment at that location (Caplan and 
Dennis, 2006; Caplan, 2017). Pre-activating the MSCs 
is not necessarily better since the effect might be too 
strong or there might be more side-effects. Although 
pre-activated MSCs do not improve migration in vitro 
or in vivo, it is possible that injection of pre-activated 
MSCs would lead to a faster or a more powerful 
anti-inflammatory effect when injected into a joint 
(Leijs et al., 2017; additional reference) This might 
be beneficial, in particular when injected in a highly 
inflamed joint. It would be interesting to compare 
pre-activated MSCs with control MSCs in a future 
experiment.
Farshid Guilak: How do you differentiate between 
soluble factors and those present within the MSC-
secreted extracellular vesicles?
Authors: The secretome used presumably contained 
both soluble factors and extracellular vesicles. 
The present set-up did not discriminate between 
these two. Which factors exerted the desired 
anti-inflammatory/regenerative effects remained 
unknown and it is crucial to investigate this aspect in 
the future to further develop this technique.
Farshid Guilak: What is the limitation of examining 
the effects of the secretome across species (human 
to mouse)?
Authors: The potency of the human MSC secretome 
was evaluated to increase the clinical translatability of 
the study. The limitation is, indeed, that some factors 
or receptors might not be cross-species-conserved 
and that the effects observed are underestimated. 
Moreover, the use of xenogeneic MSCs secretome 
might have caused more synovial inflammation, 
possibly since the extracellular vesicles can contain 
major histocompatibility complex (MHC) class I 
and II molecules (Zheng et al., 2018) and, thus, have 
reduced the analgesic effect of the MSC secretome.
Additional Reference
 Leijs MJ, van Buul GM, Lubberts E, Bos PK, 
Verhaar JA, Hoogduijn MJ, van Osch GJ (2012) 
Effect of arthritic synovial fluids on the expression 
of immunomodulatory factors by mesenchymal stem 
cells: an explorative in vitro study. Front Immunol 3: 
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